Imitex Appoints Dr. James Campbell as Chief Executive Officer

Imitex Appoints Dr. James Campbell as Chief Executive Officer

Melbourne, Australia — 19 December 2025

Imitex today announced the appointment of Dr. James Campbell as Chief Executive Officer, effective immediately.

Dr. Campbell brings more than 25 years of biotechnology experience to the role, with a strong track record in corporate strategy, business development, and deal-making in the life sciences sector. He is currently Chair of Prescient Therapeutics (ASX: PTX) and Chair of AusBiotech, and previously served as CEO of Patrys Limited (ASX: PAB).

"James is exactly the right person to lead Imitex into its next phase," said Executive Chairman Dr. Greg Collier. "His experience in strategy, transactions and capital markets will be critical as we advance our pipeline and build towards a partnership or exit."

"The science here is compelling and the timing is right," said Dr. Campbell. "MEF2 is the only first-in-class exercise mimetic target validated by independent research published in Nature, and the commercial opportunity — particularly alongside GLP-1 therapeutics — is significant. I'm looking forward to working with the team to progress this program."